查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1869953

癌症切片檢查市場規模、佔有率和趨勢分析報告：按產品、類型、應用、地區和細分市場預測（2025-2033 年）

Cancer Biopsy Market Size, Share & Trends Analysis Report By Product (Instruments, Kits And Consumables, Services), By Type (Tissue Biopsies, Liquid), By Application, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

癌症切片檢查市場摘要

2024年全球癌症切片檢查市場規模估計為323.2億美元，預計2033年將達到656.8億美元。

預計從 2025 年到 2033 年，該市場將以 8.3% 的複合年成長率成長。這一市場成長是由癌症發病率的上升所驅動的，這促使人們需要創新的診斷技術，以便為患者提供早期有效的診斷解決方案。

此外，人們對遺傳性腫瘤疾病的認知不斷提高，以及基因檢測的日益普及，預計將進一步推動癌症切片檢查行業的成長。根據美國美國癌症研究所 (NCI) 2022 年的最新數據，光是在美國就將新增約 2,000 萬例癌症病例，全球整體將有約 970 萬人死於癌症。這些龐大的數字凸顯了癌症負擔的日益加重，同時也為市場帶來了巨大的成長機會。

由於液態生物檢體技術的優勢，大規模平行基因組學（NGS）已成為一項快速發展且日新月異的技術，其應用範圍不斷擴大，涵蓋多種人類產品類型。分子突變的日益多樣化推動了NGS的普及，因為它為臨床癌症檢測提供了一種經濟高效的方法。對腫瘤異質性（同時評估多個基因）和基因譜分析的需求不斷成長，也推動了液態生物檢體的廣泛應用，預計這將進一步促進市場成長。此外，液態生物檢體已成為多種癌症診斷和篩檢的重要工具，包括攝護腺癌、乳癌、非小細胞肺癌、大腸癌和卵巢癌。

疾病發生率的上升推動了對早期癌症診斷的需求。例如，根據美國癌症協會發布的《2024年全球癌症統計》，2022年全球將新增約2,000萬例癌症病例，導致970萬人死於癌症。此外，預計到2050年，癌症病例數將達到3,500萬例。如果在癌症發生轉移之前，能夠早期發現並將其控制在原發器官內，則生存率將顯著提高，治癒的幾率也會增加。早期發現，特別是透過高效的篩檢項目，對於降低癌症死亡率至關重要。與延遲發現相比，早期發現可使患者的存活率提高5到10倍。轉移後發現的癌症，其5年癌症特異性存活率僅為21%，而早期發現且仍處於局部階段的癌症，其5年癌症特異性存活率則高達89%。

此外，各組織不斷加強宣傳活動是推動全球診斷產品需求的主要因素。美國疾病管制與預防中心（CDC）、美國（WHO）、美國國家子宮頸癌聯盟和美國預防服務工作小組等機構推動的合作與協作，預計將透過提高子宮頸癌篩檢率來促進市場成長。此外，主要市場參與者正積極採取措施提高大眾對子宮頸癌、外陰癌和陰道癌的認知，這有望鼓勵人們定期進行篩檢。

例如，2024年，印度、美國、澳洲和日本推出了「四方抗癌登月舉措」 ，重點在於消除印度-太平洋地區的子宮頸癌。同樣，2024年10月，雪梨新南威爾斯大學（UNSW）收到太古集團2590萬美元的捐款，使該校的柯比研究所能夠在七個太平洋島國（斐濟、吉裡巴斯、馬紹爾群島共和國、薩摩亞、所羅門群島、東加和瓦努阿圖）為13萬名女性進行子宮頸癌篩檢。

此外，人們對早期診斷、可用治療方案以及治療方法的進步認知不斷提高，顯著改善了患者的治療效果。根據美國癌症研究協會發布的《癌症進展報告》，2024年美國預計將新增約2,001,140例癌症病例，約有611,720人將死於癌症。

然而，高成本預計將阻礙整體市場成長。癌症診斷費用昂貴，對患者家庭帶來沉重的經濟負擔。與已開發國家相比，開發中國家缺乏政府醫療保險計劃。因此，沒有健保的中產階級患者群體無力負擔這些檢測費用。此外，許多私人保險公司也不承保開發中國家的診斷費用。因此，高成本限制了篩檢工具的普及，尤其是在開發中國家。然而，隨著印度和馬來西亞等國醫療旅遊業的快速發展，醫療和診斷方案的價格將更加親民，預計未來幾年將有所改變。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 癌症切片檢查市場變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析

第4章 癌症切片檢查市場：按產品分類的業務分析

  • 按產品分類的市場佔有率，2024 年和 2033 年
  • 產品細分儀表板
  • 市場規模、預測與趨勢分析（按產品分類，2021-2033 年）
  • 裝置
  • 套件和耗材
  • 服務

第5章 癌症切片檢查市場：按類型分類的業務分析

  • 按類型分類的市場佔有率，2024 年和 2033 年
  • 類型細分儀表板
  • 按類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 組織切片檢查
  • 液態生物檢體
  • 其他

第6章 癌症切片檢查市場：應用業務分析

  • 應用市場佔有率，2024 年和 2033 年
  • 應用細分儀表板
  • 市場規模、預測與趨勢分析（按應用領域分類，2021-2033 年）
  • 乳癌
  • 大腸直腸癌
  • 子宮頸癌
  • 肺癌
  • 攝護腺癌
  • 皮膚癌
  • 血癌
  • 腎癌
  • 肝癌
  • 胰臟癌
  • 卵巢癌
  • 其他

第7章 癌症切片檢查市場：區域估算與趨勢分析

  • 2024 年及 2033 年區域市佔率分析
  • 區域市場概覽
  • 市場規模及預測趨勢分析（2021-2033）：
  • 北美洲
    • 按國家/地區分類，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介
    • QIAGEN
    • Illumina, Inc.
    • ANGLE plc
    • BD（Becton, Dickinson and Company）
    • Myriad Genetics, Inc.
    • Hologic, Inc.
    • Biocept, Inc.
    • Thermo Fisher Scientific, Inc.
    • Danaher
    • F. Hoffmann-La Roche Ltd.
    • Lucence Health Inc.
    • GRAIL, Inc.
    • Guardant Health Inc.
    • Exact Sciences Corporation
    • Freenome Holdings, Inc.
    • Biodesix（Integrated Diagnostics）
    • Oncimmune
    • Epigenomics AG
    • HelioHealth（Laboratory for Advanced Medicine）
    • Genesystems, Inc.（Genesys Biolabs）
    • Chronix Biomedical, Inc.
    • Personal Genome Diagnostics Inc.
    • Natera, Inc.
    • Personalis Inc.
Product Code: GVR-4-68039-254-2

Cancer Biopsy Market Summary

The global cancer biopsy market size was estimated at USD 32.32 billion in 2024 and is projected to reach USD 65.68 billion by 2033, growing at a CAGR of 8.3% from 2025 to 2033. The market growth is attributed to the increasing prevalence of cancer, which is propelling the need for innovative diagnostics to provide early and effective diagnostic solutions to patients.

Moreover, the rising awareness of inherited oncology disorders and the rise in genetic testing are further anticipated to drive the growth of the cancer biopsy industry. The National Cancer Institute (NCI) 2022 update highlights that in the U.S. alone, there were approximately 20 million new cases, resulting in deaths of almost 9.7 million cancer-related deaths worldwide. These substantial figures highlight the growing cancer burden and present a significant growth opportunity for the market.

Due to the advantages of liquid biopsy technologies, massive parallel or NGS has emerged as a rapidly growing and evolving technology with increasing applications in various human Products. An increase in alterations of molecules in various types supports the usage of NGS in clinical settings, as it provides a cost- and time-effective way of detecting cancer. Tumor heterogeneity (evaluating different genes at the same time), along with the need for gene profiling, has increased the use of liquid biopsy, which is expected to propel market growth. Moreover, for various applications, such as prostate, breast, non-small-cell lung, colorectal, and ovarian cancer, liquid biopsy is used for diagnostic & screening, making it an important tool.

The increasing incidence of disease is propelling the demand for the diagnosis of cancers at early stages. For instance, as per Global Cancer Statistics 2024, reported by the American Cancer Society, approximately 20 million cancer cases were newly diagnosed in 2022, and 9.7 million people died from it globally. Moreover, the number of cancer cases is predicted to reach 35 million by 2050. When cancer is discovered early and is contained to the organ of origin before it has a chance to spread, survival rates drastically increase, and it is more likely to be effectively cured. Early detection is crucial for lowering cancer-related mortality, especially through efficient screening programs. Early detection increases patient survival rates by 5 to 10 times more than late detection. The 5-year cancer-specific survival rate is only 21% when cancer is discovered after it has spread, as opposed to 89% when it is found early & still localized.

Furthermore, the increasing number of initiatives by various organizations to raise awareness is a major reason for the growing demand for diagnostic products worldwide. Collaborations and partnerships undertaken by CDC, WHO, the National Cervical Cancer Coalition, the U.S. Preventive Services Task Force, & others are expected to drive market growth by increasing cervical cancer screening rates. In addition, major market players are undertaking initiatives to increase awareness about cervical, vulvar, and vaginal cancer, which is likely to encourage people to opt for screening at regular intervals.

For instance, in 2024, India, the U.S., Australia, and Japan launched the Quad Cancer Moonshot Initiative, which was specifically focused on eliminating cervical cancer across the Indo-Pacific region. Similarly, in October 2024, the University of New South Wales (UNSW) Sydney received a donation of USD 25.9 million from the Swire Group. This funding allowed the Kirby Institute at UNSW Sydney to screen 130,000 women in seven Pacific countries, including Fiji, Kiribati, the Republic of Marshall Islands, Samoa, Solomon Islands, Tonga, and Vanuatu, for cervical cancer.

Moreover, awareness among people about early diagnosis and available treatment options and advancements in treatments has substantially improved patient outcomes. According to a Cancer Progress Report published by the American Association for Cancer Research, it was expected that in the U.S., around 2,001,140 new cases of cancer would be diagnosed in 2024, and approximately 611,720 people might die from the Disease.

However, the high cost of diagnostic tests is anticipated to hamper the overall market growth. Diagnostic cancer tests are expensive, increasing the financial burden on families of patients. The government insurance framework is less well-defined in developing countries than in developed countries. Thus, the middle-class patient population who are uninsured cannot afford these tests. In addition, many private insurance players do not cover costs associated with diagnosis in developing countries. As a result, the high cost of diagnosis is limiting the adoption of screening tools, especially in developing countries. However, the scenario is expected to change in the coming years due to booming medical tourism in countries such as India and Malaysia, wherein healthcare treatments & diagnostic solutions are becoming affordable.

Global Cancer Biopsy Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cancer biopsy market report based on product, type, application, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments
  • Kits & Consumables
  • Services
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Tissue Biopsies
    • Needle Biopsies
    • Surgical Biopsies
  • Liquid Biopsies
    • Fine Needle Aspiration (FNA)
    • Core Needle Biopsy (CNB)
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancers
  • Lung Cancers
  • Prostate Cancers
  • Skin Cancers
  • Blood Cancers
  • Kidney Cancers
  • Liver Cancers
  • Pancreatic Cancers
  • Ovarian Cancers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cancer Biopsy Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Cancer Biopsy Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Instruments
    • 4.4.1. Instruments Market, 2021 - 2033 (USD Million)
  • 4.5. Kits and Consumables
    • 4.5.1. Kits and Consumables Market, 2021 - 2033 (USD Million)
  • 4.6. Services
    • 4.6.1. Services Market, 2021 - 2033 (USD Million)

Chapter 5. Cancer Biopsy Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2033
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 5.4. Tissue Biopsies
    • 5.4.1. Tissue Biopsies Market, 2021 - 2033 (USD Million)
      • 5.4.1.1. Needle Biopsies
        • 5.4.1.1.1. Needle Biopsies Market, 2021 - 2033 (USD Million)
      • 5.4.1.2. Surgical Biopsies
        • 5.4.1.2.1. Surgical Biopsies Market, 2021 - 2033 (USD Million)
  • 5.5. Liquid Biopsies
    • 5.5.1. Liquid Biopsies Market, 2021 - 2033 (USD Million)
      • 5.5.1.1. Fine Needle Aspiration (FNA)
        • 5.5.1.1.1. Fine Needle Aspiration (FNA) Market, 2021 - 2033 (USD Million)
      • 5.5.1.2. Core Needle Biopsy (CNB)
        • 5.5.1.2.1. Core Needle Biopsy (CNB) Market, 2021 - 2033 (USD Million)
  • 5.6. Others

Chapter 6. Cancer Biopsy Market: Application Business Analysis

  • 6.1. Application Market Share, 2024 & 2033
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 6.4. Breast Cancer
    • 6.4.1. Breast Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Colorectal Cancer
    • 6.5.1. Colorectal Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Cervical Cancers
    • 6.6.1. Cervical Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Lung Cancers
    • 6.7.1. Lung Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Prostate Cancers
    • 6.8.1. Prostate Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Skin Cancers
    • 6.9.1. Skin Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Blood Cancers
    • 6.10.1. Blood Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Kidney Cancers
    • 6.11.1. Kidney Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12. Liver Cancers
    • 6.12.1. Liver Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.13. Pancreatic Cancers
    • 6.13.1. Pancreatic Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.14. Ovarian Cancers
    • 6.14.1. Ovarian Cancers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.15. Others
    • 6.15.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cancer Biopsy Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Cancer Biopsy Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. U.S. Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Canada Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Mexico Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. UK Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Germany Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. France Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Italy Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Spain Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Denmark Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Sweden Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Norway Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Japan Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. China Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. India Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Australia Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. South Korea Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Thailand Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Japan Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. China Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. South Africa Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Saudi Arabia Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. UAE Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Kuwait Cancer Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. QIAGEN
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Illumina, Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. ANGLE plc
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. BD (Becton, Dickinson and Company)
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Myriad Genetics, Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Hologic, Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Biocept, Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Thermo Fisher Scientific, Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Danaher
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. F. Hoffmann-La Roche Ltd.
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Lucence Health Inc.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. GRAIL, Inc.
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Guardant Health Inc.
      • 8.5.13.1. Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Product Benchmarking
      • 8.5.13.4. Strategic Initiatives
    • 8.5.14. Exact Sciences Corporation
      • 8.5.14.1. Overview
      • 8.5.14.2. Financial Performance
      • 8.5.14.3. Product Benchmarking
      • 8.5.14.4. Strategic Initiatives
    • 8.5.15. Freenome Holdings, Inc.
      • 8.5.15.1. Overview
      • 8.5.15.2. Financial Performance
      • 8.5.15.3. Product Benchmarking
      • 8.5.15.4. Strategic Initiatives
    • 8.5.16. Biodesix (Integrated Diagnostics)
      • 8.5.16.1. Overview
      • 8.5.16.2. Financial Performance
      • 8.5.16.3. Product Benchmarking
      • 8.5.16.4. Strategic Initiatives
    • 8.5.17. Oncimmune
      • 8.5.17.1. Overview
      • 8.5.17.2. Financial Performance
      • 8.5.17.3. Product Benchmarking
      • 8.5.17.4. Strategic Initiatives
    • 8.5.18. Epigenomics AG
      • 8.5.18.1. Overview
      • 8.5.18.2. Financial Performance
      • 8.5.18.3. Product Benchmarking
      • 8.5.18.4. Strategic Initiatives
    • 8.5.19. HelioHealth (Laboratory for Advanced Medicine)
      • 8.5.19.1. Overview
      • 8.5.19.2. Financial Performance
      • 8.5.19.3. Product Benchmarking
      • 8.5.19.4. Strategic Initiatives
    • 8.5.20. Genesystems, Inc. (Genesys Biolabs)
      • 8.5.20.1. Overview
      • 8.5.20.2. Financial Performance
      • 8.5.20.3. Product Benchmarking
      • 8.5.20.4. Strategic Initiatives
    • 8.5.21. Chronix Biomedical, Inc.
      • 8.5.21.1. Overview
      • 8.5.21.2. Financial Performance
      • 8.5.21.3. Product Benchmarking
      • 8.5.21.4. Strategic Initiatives
    • 8.5.22. Personal Genome Diagnostics Inc.
      • 8.5.22.1. Overview
      • 8.5.22.2. Financial Performance
      • 8.5.22.3. Product Benchmarking
      • 8.5.22.4. Strategic Initiatives
    • 8.5.23. Natera, Inc.
      • 8.5.23.1. Overview
      • 8.5.23.2. Financial Performance
      • 8.5.23.3. Product Benchmarking
      • 8.5.23.4. Strategic Initiatives
    • 8.5.24. Personalis Inc.
      • 8.5.24.1. Overview
      • 8.5.24.2. Financial Performance
      • 8.5.24.3. Product Benchmarking
      • 8.5.24.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Cancer Biopsy Market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 5. Global Cancer Biopsy Market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6. North America Cancer Biopsy Market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 8. North America Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 9. North America Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 10. U.S. Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 11. U.S. Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 12. U.S. Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 13. Canada Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 14. Canada Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 15. Canada Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 16. Mexico Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 17. Mexico Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 18. Mexico Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 19. Europe Cancer Biopsy Market, by Country, 2021 - 2033 (USD Million)
  • Table 20. Europe Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 21. Europe Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 22. Europe Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 23. UK Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 24. UK Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 25. UK Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 26. Germany Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 27. Germany Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 28. Germany Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 29. France Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 30. France Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 31. France Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 32. Italy Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 33. Italy Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 34. Italy Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 35. Spain Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 36. Spain Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 37. Spain Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 38. Norway Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 39. Norway Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 40. Norway Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 41. Denmark Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 42. Denmark Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 43. Denmark Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 44. Sweden Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 45. Sweden Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 46. Sweden Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 47. Asia Pacific Cancer Biopsy Market, by Country, 2021 - 2033 (USD Million)
  • Table 48. Asia Pacific Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 49. Asia Pacific Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 50. Asia Pacific Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 51. Japan Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 52. Japan Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 53. Japan Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 54. China Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 55. China Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 56. China Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 57. India Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 58. India Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 59. India Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 60. Australia Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 61. Australia Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 62. Australia Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 63. South Korea Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 64. South Korea Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 65. South Korea Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 66. Thailand Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 67. Thailand Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 68. Thailand Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 69. Latin America Cancer Biopsy Market, by country, 2021 - 2033 (USD Million)
  • Table 70. Latin America Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 71. Latin America Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 72. Latin America Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 73. Brazil Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 74. Brazil Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 75. Brazil Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 76. Argentina Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 77. Argentina Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 78. Argentina Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 79. Middle East & Africa Cancer Biopsy Market, by Country, 2021 - 2033 (USD Million)
  • Table 80. Middle East & Africa Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 81. Middle East & Africa Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 82. Middle East & Africa Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 83. South Africa Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 84. South Africa Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 85. South Africa Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 86. Saudi Arabia Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 87. Saudi Arabia Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 88. Saudi Arabia Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 89. UAE Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 90. UAE Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 91. UAE Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)
  • Table 92. Kuwait Cancer Biopsy Market, by Product, 2021 - 2033 (USD Million)
  • Table 93. Kuwait Cancer Biopsy Market, by Type, 2021 - 2033 (USD Million)
  • Table 94. Kuwait Cancer Biopsy Market, by Application, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Cancer Biopsy Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and Product outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Cancer Biopsy Market dynamics
  • Fig. 12 Cancer Biopsy Market: Porter's five forces analysis
  • Fig. 13 Cancer Biopsy Market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Instruments market, 2021 - 2033 (USD Million)
  • Fig. 16 Kits and Consumables market, 2021 - 2033 (USD Million)
  • Fig. 17 Services market, 2021 - 2033 (USD Million)
  • Fig. 18 Type market, 2021 - 2033 (USD Million)
  • Fig. 19 Tissue Biopsies market, 2021 - 2033 (USD Million)
  • Fig. 20 Liquid Biopsies market, 2021 - 2033 (USD Million)
  • Fig. 21 Others market, 2021 - 2033 (USD Million)
  • Fig. 22 Application market, 2021 - 2033 (USD Million)
  • Fig. 23 Breast Cancer market, 2021 - 2033 (USD Million)
  • Fig. 24 Colorectal Cancer market, 2021 - 2033 (USD Million)
  • Fig. 25 Cervical Cancer market, 2021 - 2033 (USD Million)
  • Fig. 26 Lung Cancer market, 2021 - 2033 (USD Million)
  • Fig. 27 Prostate Cancer market, 2021 - 2033 (USD Million)
  • Fig. 28 Skin Cancer market, 2021 - 2033 (USD Million)
  • Fig. 29 Blood Cancer market, 2021 - 2033 (USD Million)
  • Fig. 30 Kidney Cancer market, 2021 - 2033 (USD Million)
  • Fig. 31 Liver Cancer market, 2021 - 2033 (USD Million)
  • Fig. 32 Pancreatic Cancer market, 2021 - 2033 (USD Million)
  • Fig. 33 Ovarian Cancer market, 2021 - 2033 (USD Million)
  • Fig. 34 Others market, 2021 - 2033 (USD Million)
  • Fig. 35 Cancer Biopsy Market revenue, by region
  • Fig. 36 Regional marketplace: Key takeaways
  • Fig. 37 North America Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 38 U.S. country dynamics
  • Fig. 39 U.S. Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 40 Canada country dynamics
  • Fig. 41 Canada Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 42 Mexico country dynamics
  • Fig. 43 Mexico Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 44 Europe Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 45 UK country dynamics
  • Fig. 46 UK Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 47 Germany country dynamics
  • Fig. 48 Germany Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 49 France country dynamics
  • Fig. 50 France Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 51 Italy country dynamics
  • Fig. 52 Italy Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 53 Spain country dynamics
  • Fig. 54 Spain Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 55 Norway country dynamics
  • Fig. 56 Norway Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 57 Sweden country dynamics
  • Fig. 58 Sweden Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 59 Denmark country dynamics
  • Fig. 60 Denmark Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 61 Asia Pacific Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 62 Japan country dynamics
  • Fig. 63 Japan Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 64 China country dynamics
  • Fig. 65 China Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 66 India country dynamics
  • Fig. 67 India Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 68 Australia country dynamics
  • Fig. 69 Australia Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 70 South Korea country dynamics
  • Fig. 71 South Korea Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 72 Thailand country dynamics
  • Fig. 73 Thailand Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 74 Latin America Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 75 Brazil country dynamics
  • Fig. 76 Brazil Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 77 Argentina country dynamics
  • Fig. 78 Argentina Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 79 MEA Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 80 South Africa country dynamics
  • Fig. 81 South Africa Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 82 Saudi Arabia country dynamics
  • Fig. 83 Saudi Arabia Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 84 UAE country dynamics
  • Fig. 85 UAE Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 86 Kuwait country dynamics
  • Fig. 87 Kuwait Cancer Biopsy Market, 2021 - 2033 (USD Million)
  • Fig. 88 Company categorization
  • Fig. 89 Company market position analysis
  • Fig. 90 Strategic framework